Dietary Supplementation of Lactobacillus brevis Normalizes Metabolic Parameters in Mouse with Obesity and Hyperglycemia

Abstract

Aims: Exploration of the ameliorative effects of Lactobacillus brevis on glycemic and obesity parameters in high fat diet (HFD) fed hyperglycemic Swiss albino mice. Study Design: HFD with 58% fat, 25.6% carbohydrate, and 16.4% protein was fed to mice to develop metabolic syndrome. The experimental group of obese mice was fed with oral supplement of L. brevis for 28 days and the metabolic parameters of the mice are compared with control groups. The experiments were performed in triplicate. Place and Duration of Study: The study was executed in the Laboratory of Immunology and Microbiology, Department of Zoology, University of North Bengal situated in the Darjeeling district of West Bengal, India in 2020-21. Methodology: ‘ND’, fed with normal pellet-based diet; ‘HFD’, fed with HFD diet and 10% sucrose water and ‘HFD + LB’, fed with diet same as ’HFD’ group along with 1× 108 CFU of L. brevis (for each animal/day) from 22nd day onwards. At the end of experiment (on 50th day) the body weights, Oral glucose tolerance test (OGTT), fasting blood glucose (FBG) levels and serum Lipid Profile were measured. Results: the HFD group showed significantly high FBG levels (203.66 ± 8.73 mg/dL) when compared with the ND group (130± 2 mg/dL) but the FBG levels in HFD + LB group (163.66 ± 4.72 mg/dL) were not as significantly higher as the HFD group. OGTT test revealed L. brevis helped to resist the persistent hyperglycemic effects. It was seen that the levels of lipids like Triglycerides and Total cholesterol in HFD + LB group were in normal range and similar like that of the ND groups (172.22 ± 3.854 mg/dL and 134.89 ± 4.705 mg/dL). Conclusion: These findings indicate strong association for probiotic use of L. brevis as a potent preventative measure to combat the detrimental metabolic changes.